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Objectives: to assess the rifampicin binding and elution characteristics for three protein-sealed vascular grafts.
Design: in vitro study.
Materials: Cardial and Hemashield collagen-sealed and the DeBakey/Vasculour albumin-sealed vascular grafts.
Methods: the grafts were soaked in a 60 000 mg/l solution of rifampicin at 37 °C for 15 min. Bound drug was eluted
from the grafts at 37 °C and at timed intervals the concentrations of rifampicin remaining in the grafts were determined.
Results: although all three grafts contained high concentrations of rifampicin immediately after soaking these rapidly fell
on washing and only a small fraction of the adsorbed rifampicin was tightly bound to the grafts. Rifampicin loading of
this tightly bound fraction was similar for the two collagen-sealed grafts (1.7–2.0 mg/kg) but higher for the albumin-
sealed graft (16.0 mg/kg). Elution of the tightly bound fraction appeared to follow first-order kinetics with elimination
half-lives of 89–141 h. The concentrations of rifampicin remaining in the grafts after eight days were above those needed
to inhibit sensitive staphylococci and were 0.7 mg/kg (collagen-sealed grafts) to 3.7 mg/kg (albumin-sealed graft).
Conclusions: there is broad equivalence between the rifampicin binding and elution for the two collagen-sealed grafts,
but there appears to be slightly higher binding for the albumin-sealed graft.
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Introduction We have previously been able to demonstrate equi-
valence in rifampicin binding and elution for two
Despite significant improvements in the management types of gelatin-sealed and one type of collagen-sealed
of patients receiving vascular grafts infection still oc- graft and identified that only a small fraction of the
curs in up to 5% of patients, with an associated high rifampicin loading is tightly bound to the graft.11 In
rate of mortality.1,2 The value of locally applied anti- this study we report comparative in vitro data for the
microbial is well established in the field of ortho- kinetics of rifampicin binding and elution for three
paedics, where antimicrobial-containing cement is different commercially available protein-sealed vas-
used routinely during arthroplasty3 and in recent years cular grafts, two sealed with collagen and one sealed
the potential benefits of impregnating vascular grafts with albumin.
with rifampicin have been evaluated. Animal studies
using grafts which have been soaked in rifampicin
have demonstrated protection against bacterial chal-
Materials and Methodslenge at the time of operation, in the postoperative
period one or two days after implantation and in
The study methods were based upon those previouslythe replacement of infected grafts,4–10 while laboratory
reported.11 The grafts chosen for study were the Hema-studies have demonstrated that rifampicin binds to
shield (Meadox Microvel, Oakland, NJ, U.S.A.) andgelatin-, albumin- and collagen-sealed grafts and that
Cardial (Impra Division, Bard, U.K.) collagen-sealedthe extent of rifampicin uptake by the grafts varies
grafts and the DeBakey/Vasculour (Bard, Billeriica,with both the concentration and length of exposure
MA, U.S.A.) albumin-sealed graft. The binding of ri-to rifampicin prior to implant.11–15 However, because
fampicin to the grafts was based upon the protocolinfection rates are low, prospective studies using ri-
recommended by Meadox Microvel (Hemashield: Ri-fampicin pretreatment of grafts have not as yet dem-
fampicin soaking procedure); sections of graft ap-onstrated a clear benefit associated with rifampicin-
treated grafts.16–19 proximately 100 mm in length were immersed in a
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Table. The concentrations of rifampicin (mg/kg dry weight) in60 000 mg/l solution of rifampicin which was prepared
samples of rifampicin-bound graft collected at timed intervalsby the dilution of 300 mg vials of rifampicin (Ri- during elution in PBS at 37°C.
mactane, Ciba) in sterile water. After incubation at
Time Rifampicin Concentration37 °C for 15 min the sections of graft were removed
(h) mg/kgfrom the rifampicin solution, briefly washed in
DeBakey/ Hemashieldb CardialbRinger’s solution to remove any rifampicin solution
Vasculouraremaining on the graft, and each section of graft was
placed in a sterile 500 ml conical flask. 300 ml of sterile 0 10689.03 7174.46 7424.96
25 85.29 2.19 2.47phosphate buffered saline (PBS) was then added to
29 50.10 1.67 1.48each flask and the flasks were incubated at 37 °C. At
46 19.56 1.58 1.44regular intervals, samples (approx 1 cm2) of the grafts 53 10.79 1.53 —
70 9.03 1.50 1.01were aseptically removed; these were then stored at
120 6.40 1.20 0.85-70 °C until assayed. The PBS surrounding the grafts
142 5.24 0.93 0.75was replaced with fresh PBS at regular intervals and 173 4.22 0.86 0.73
190 3.71 0.72 0.67during the eight day course of the experiment 35
changes of PBS were undertaken. Samples of graft were a, Albumin-sealed graft; b, Collagen-sealed graft.thawed at room temperature then dried to constant
weight at 56 °C (typically 1 h). A volume of methanol
equivalent to twice the weight of the graft sample
(1 mlz1 g) was then added to each sample of graft
and these were left at 4 °C overnight for the rifampicin
to extract. Samples of the methanol were assayed for
rifampicin by high-performance liquid chromato-
graphy using a Hypersil 5ODS column (150·4 mm)
and a mobile phase composed of 0.1 M phosphate
buffer (pH 6) at acetonitrile (70:30) which was pumped
to a flow of 2 ml/min. Detection of rifampicin was by
UV absorbance at 254 nm with collection of data using
a computing integrator. Quantitation of rifampicin
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Fig. 1. The concentrations of rifampicin in samples of rifampicin-prepared in methanol. bound graft following elution in PBS. (O) DeBakey/Velour; (E)
hemashield; (M) cardial; (- -) MIC for S. aureus.
for the rest of the elution period (Fig.). During this
Results slower elution phase the wash-out of rifampicin from
the grafts was fitted to a first-order kinetic modelFollowing incubation at 37 °C for 15 min in a which gave apparent half-lives of 141 h (Hemashield)60 000 mg/ml solution of rifampicin, all three grafts and 134 h (Cardial) for the two collagen-sealed graftswere stained a bright orange colour. However, once and 89 h for the DeBakey/Vasculour albumin-sealedplaced into the PBS solution most of the bound ri- graft. Extrapolation of the slow elution phase back tofampicin rapidly diffused out into the PBS and by time zero gave theoretical rifampicin loading for theabout 5 h after being placed into the PBS it was no grafts of 2.0 mg/kg (Hemashield) and 1.7 mg/kglonger possible to detect visually rifampicin binding (Cardial) for the two collagen-sealed grafts andto the two collagen-sealed grafts. The albumin-sealed 16.0 mg/kg (De-Bakey/Vasculour) for the albumin-graft was a natural buff/orange colour and con- sealed graft.sequently it was not possible to make visual as-
sessments of rifampicin binding once placed in PBS.
The concentrations of rifampicin found in the methanol
washings from the three grafts were corrected for the Discussion
weight of graft, expressed as mg/kg dry weight of
graft, and are shown in the Table. As we have previously reported,11 and has been found
by others,12,13 during the first few hours of elution ofAs seen in earlier studies, concentrations of
rifampicin fell rapidly during the initial part of the rifampicin from the grafts concentrations fell rapidly
for all three grafts. However, once this loosely boundstudy for all three grafts and then much more slowly
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fraction had been removed there was a much slower Although the two collagen-sealed grafts used in
this study demonstrated broadly similar binding andelution of the remaining rifampicin from the grafts,
confirming a second and much more tightly bound elution characteristics for rifampicin (Fig.), there were
slight differences between them in terms of bothfraction. The tightly bound fraction eluted with an
apparent half-life of 89–141 h, depending on the graft, rifampicin loading and elution half-lives. However,
these differences were small, did not reach statisticaland extrapolation back to time zero from this phase
suggests that only a very small amount of the significance, and we would not consider them im-
portant from a clinical point of view, since after 8 daysrifampicin is tightly bound to the graft (1.7–
16.0 mg/kg). Although these figures are slightly dif- of elution rifampicin concentrations were 0.72 mg/kg
(Hemashield) and 0.67 mg/kg (Cardial) of dry weight.ferent from our original data for the Hemashield
graft,11 they are broadly similar and also consistent Even allowing for rehydration of the protein sealant
in the grafts, these figures are an order of magnitudewith the findings of both Malassiney et al.12 and Gehtan
et al.15 However, they are substantially different to the higher than the minimal inhibitory concentrations
(MICs) reported for staphylococci20,21 and are thereforefigures reported by Galdbart et al.,13 where half-lives
of 4–5.5 h were found. In the Galdbart study cal- likely to represent adequate prophylactic con-
centrations.culations of half-life were made during the early elu-
tion phase, where most of the drug eluting from the Although the elution of rifampicin from the al-
bumin-sealed graft was slightly quicker (half-life 89 h)graft was from the loosely bound fraction rather than
from the tightly bound fraction. As it is probably than seen with the collagen-sealed grafts, the total
rifampicin loading was approximately ten times higheronly the tightly bound fraction of rifampicin that
contributes to antimicrobial prophylaxis beyond the at 16.0 mg/kg. As a consequence, rifampicin con-
centrations in the albumin-sealed graft were sig-immediate postoperative period, we would stress the
importance of looking at this phase of elution when nificantly higher than in the two collagen-sealed grafts
throughout the study period, and after 8 days of elutionmaking comparisons between grafts.
In our original evaluation of the Hemashield graft11 rifampicin concentrations were 3.7 mg/kg compared
with approximately 0.7 mg/kg in the two collagen-we found a rifampicin loading of 1.2 mg/kg and an
elution half-life of 76 h, as compared to figures of sealed grafts. Although it is difficult to comment on
the likely clinical significance of these findings, it2.0 mg/kg and 141 h, respectively, in this study. It is
possible that these slight differences could have res- would appear logical to assume that higher rifampicin
concentrations would be associated with a prolongedulted from variability between different batches of
grafts or from methodological differences between the period of prophylaxis.
In our earlier study we looked at two gelatin-sealedtwo experiments. In the original evaluation a loading
concentration of 1000 mg/l was used, as compared grafts in comparison with the Hemashield collagen-
sealed graft, finding the elution and binding char-with the 60 000 mg/l used in this study, and elution
of rifampicin was only followed to day 5 compared acteristics of rifampicin from the three grafts to be
broadly similar.11 In this study we have shown equi-with day 8 in this study. Although Malassiney et al.12
were able to demonstrate slightly enhanced uptake of valence between the Hemashield and Cardial collagen-
sealed grafts for the binding and elution of rifampicin,rifampicin between solutions of 1 000 mg/l and
10 000 mg/l the differences we have found in ri- but a higher uptake of rifampicin by the DeBakey/
Vasculour albumin-sealed graft. We therefore concludefampicin loading between 1000 mg/l (1.2 mg/kg) and
60 000 mg/l (2.0 mg/kg) solutions would suggest that that there are no significant differences between the
binding and elution characteristics for the four com-any such differences are unlikely to be of clinical
significance. In our earlier study rifampicin con- mercially available gelatin- and collagen-sealed grafts
we have tested but that the albumin-sealed graft ex-centrations were only followed up to five days after
soaking and resulted in half-lives which were lower hibits enhanced uptake of rifampicin. However, for all
of the grafts the rifampicin is tightly bound to thethan found in this study where concentrations were
followed for eight days. This would suggest that the graft and care needs to be taken when comparing
rifampicin levels in grafts with MICs determined usinguse of first-order kinetics to describe the elution of
rifampicin from the grafts is an oversimplification free rifampicin. Furthermore, large clinical studies are
still required to establish the role of rifampicin pre-and that the rate of elution slows slightly with time,
indicating that there are probably multiple sites, with treatment of grafts, since due to the low infection rates
early studies have not been able to demonstrate adifferent affinity constants, to which rifampicin is
binding. significant reduction in the 2-year infection rate for
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